제품 > 항체 > Biosimilar Antibody

Human SIRPα Monoclonal Antibody (YR0021)

Human SIRPα ELISA Standard Curve. Direct ELISA binding curve demonstrating the recognition of Human Anti-Human SIRPα (Research Grade Anzurstobart Biosimilar) Monoclonal Antibody to SIRPα. The target protein was coated onto the microplate well surface, followed by binding of the antibody. Neutravidin HRP conjugate was used for detection.

Basic Information

Clone	Anzurstobart Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Target Background

Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.